Posts tagged Phase 1 data
WB starts Akari Therapeutics at OP

William Blair launched coverage of Akari Therapeutics (NASDAQ:AKTX) with an “outperform” rating. The stock closed at $11.62 on April 5.

Read More
Ladenburg starts Checkpoint Therapeutics at buy

Ladenburg Thalmann initiated coverage of Checkpoint Therapeutics (OTCQX:CKPT) with a “buy” rating and $20 price target. The stock closed at $13 on March 21.

Read More
Juniper Pharma COL-1077 Phase 1 data published

The peer-reviewed medical journal, Clinical Pharmacology in Drug Development, has published the combined results of two Phase 1 clinical trials by Juniper Pharmaceuticals (NASDAQ:JNP) that demonstrated the safety and pharmacokinetics of Juniper’s lidocaine bioadhesive vaginal gel, COL-1077.

The article reports that in women treated with COL-1077, lidocaine was absorbed through vaginal tissue and into the systemic circulation in a dose-proportional manner, with little systemic accumulation.

Read More